Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

Latinovic O; Le N; Reitz M; Pal R; DeVico A; Foulke JS; Redfield RR; Heredia A

首页> 外文期刊>AIDS >Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

【24h】

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

机译：maraviroc和CCR5抗体HGS004在原代细胞中协同抑制R5 HIV-1：对治疗和预防的意义。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

CCR5 blockers inhibit CCR5-tropic (R5) HIV-1, including strains resistant to other antiretrovirals. We demonstrate that the CCR5 antibody HGS004 and the CCR5 antagonist maraviroc have potent antiviral synergy against R5 HIV-1, translating into dose reductions of more than 10-fold for maraviroc and more than 150-fold for HGS004. These data, together with the high barrier of resistance to HGS004, suggest that combinations of maraviroc and HGS004 could provide effective preventive and therapeutic strategies against R5 HIV-1.

机译：CCR5阻滞剂抑制CCR5-tropic（R5）HIV-1，包括对其他抗逆转录病毒药物有抗性的菌株。我们证明，CCR5抗体HGS004和CCR5拮抗剂maraviroc具有针对R5 HIV-1的有效抗病毒协同作用，转化为maraviroc的剂量降低了10倍以上，而HGS004的剂量降低了150倍以上。这些数据，以及对HGS004的高耐药性屏障表明，maraviroc和HGS004的组合可以提供针对R5 HIV-1的有效预防和治疗策略。

著录项

来源
《AIDS》 |2011年第9期|共4页
作者
Latinovic O; Le N; Reitz M; Pal R; DeVico A; Foulke JS; Redfield RR; Heredia A;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention. [J] . Latinovic O, Le N, Reitz M, AIDS . 2011,第9期

机译：maraviroc和CCR5抗体HGS004在原代细胞中协同抑制R5 HIV-1：对治疗和预防的意义。
2. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection [J] . Isabella Bon, Alberto Clò, Marco Borderi, International journal of infectious diseases : . 2013,第10期

机译：R5菌株在经过多重治疗的HIV受试者中的患病率以及包括maraviroc在内的新方案对一组CCR5嗜性HIV-1感染患者的影响
3. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. [J] . Meng G, Wei X, Wu X, Nature medicine . 2002,第2期

机译：原肠小肠上皮细胞选择性地将R5 HIV-1转移至CCR5 +细胞。
4. Predicting the Co-receptors (CCR5 and CXCR4) of the Viruses R5, X4 and R5X4 that Cause AIDS (HIV-1) in Cells CD4 using The Bayes Classifier [C] . Francisco Javier Luna Rosas, Julio Cesar Martinez Romo, Carlos Alejandro de Luna Ortega, International Conference on Bioinformatics and Computational Biology . 2014

机译：预测病毒R5，X4和R5X4的共同受体（CCR5和CXCR4），其使用贝叶斯分类器导致细胞CD4中的艾滋病（HIV-1）
5. Studies of Protein Interactions and Knowledge-Based Drug Design: (A) The Electrostatic Nature of Recognition Between HIV-1 gp120 V3 Loop and Coreceptors CCR5/CXCR4, (B) Complement System Inhibition by Compstatin Family Peptides [D] . Lopez de Victoria Suarez, Aliana 2012

机译：蛋白质相互作用和基于知识的药物设计的研究：（A）HIV-1 gp120 V3环与共受体CCR5 / CXCR4之间识别的静电性质，（B）坎普他汀家族肽对补体系统的抑制作用
6. Synergistic Inhibition of R5 HIV-1 by Maraviroc and CCR5 Antibody HGS004 in Primary Cells: Implications for Treatment and Prevention [O] . OLGA LATINOVIC, NHUT LE, MARVIN REITZ, -1

机译：R5 HIV-1的协同抑制作用马拉韦罗和CCR5抗体HGs004在原代细胞：对治疗和预防
7. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells [O] . Latinovic Olga, Reitz Marvin, Le Nhut M., 2011

机译：CCR5抗体HGS004和HGS101优先抑制药物结合的CCR5感染并恢复原代细胞中抗Maraviroc的HIV-1的药物敏感性

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

摘要

著录项

相似文献

相关主题

期刊订阅